(Reuters) -Charles River Laboratories said on Wednesday it had reached an agreement with activist investor Elliott Investment Management and added four new directors to its board, sending its shares up nearly 24% to $143 before the bell. The contract research firm, which has Elliott as its largest investor, said it will initiate a comprehensive review of its business, including an examination of various other alternatives to enhance long-term stockholder value. The investor's exact stake in the company could not be determined. Elliott's Global Head of Engagement Steven Barg, who previously served on the boards of drug distributor Cardinal Health and contract drug manufacturer Catalent, will join Charles River's board. The other three independent directors include Rapport Therapeutics CEO Abe Ceesay, former ImmunoGen CEO Mark Enyedy and Rio Tinto Lithium CEO Paul Graves. Following the new appointments, which will be effective after the annual shareholders meeting on May 20, the board will consist of eleven directors, nine of whom will be independent. Reuters had reported on the settlement earlier on Wednesday. Charles River's shares fell last month after the U.S. Food and Drug Administration announced plans to phase out conventional animal testing for monoclonal antibodies and other drugs to focus on more effective, human-relevant methods. (Reporting by Siddhi Mahatole and Sriparna Roy in Bengaluru; Editing by Shreya Biswas)
Charles River to add new directors, review business in agreement with Elliott
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...